Report on the quality of life analysis from the phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer.
Eur J Cancer
; 36(6): 759-65, 2000 Apr.
Article
in En
| MEDLINE
| ID: mdl-10762749
ABSTRACT
This report examines the quality of life (QOL) of 215 patients entered into a randomised trial between pion and photon radiotherapy for prostate cancer at a single institution. The survival and local control results of the trial were equivalent in both arms. A modification of the Rotterdam Symptom Checklist (RSCL) was used to assess QOL. Global QOL, toxicity and physical scores were found to be worse in pion-treated patients at the end of treatment (P<0.001, P<0.001, and P=0.02 respectively). There are no long-term differences in the QOL of pion- versus photon-treated patients. Sexual function was a concern for patients even at baseline. There was a progressive loss of sexual interest and erectile function. There was a significant impact from hormonal therapy at relapse. Hormonal treatment produced a stepwise significant worsening in global QOL, particularly for physical and psychological domains.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Quality of Life
/
Adenocarcinoma
/
Photons
/
Mesons
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eur J Cancer
Year:
2000
Document type:
Article
Affiliation country:
Canada